Patents by Inventor Nuria Tubau-Juni
Nuria Tubau-Juni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230192652Abstract: Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.Type: ApplicationFiled: January 13, 2023Publication date: June 22, 2023Applicant: Landos Biopharma, Inc.Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
-
Publication number: 20230128450Abstract: Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat conditions such as autoimmune diseases, allergic diseases, chronic and/or inflammatory central nervous system diseases, chronic and/or inflammatory respiratory diseases, cancer, and infectious diseases. Exemplary conditions include multiple sclerosis, asthma, Alzheimer's disease, Parkinson's disease, neuroinflammation resulting from, for example, stroke, traumatic brain injury, or spinal cord injury, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and inflammatory bowel disease.Type: ApplicationFiled: December 20, 2022Publication date: April 27, 2023Applicant: Landos Biopharma, Inc.Inventors: Josep Bassaganya-Riera, Andrew Leber, Nuria Tubau-Juni, Raquel Hontecillas
-
Patent number: 11597717Abstract: Provided are compounds of Formula Y-Z: The compounds target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.Type: GrantFiled: September 29, 2021Date of Patent: March 7, 2023Assignee: Landos Biopharma, Inc.Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
-
Patent number: 11548885Abstract: Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat conditions such as autoimmune diseases, allergic diseases, chronic and/or inflammatory central nervous system diseases, chronic and/or inflammatory respiratory diseases, cancer, and infectious diseases. Exemplary conditions include multiple sclerosis, asthma, Alzheimer's disease, Parkinson's disease, neuroinflammation resulting from, for example, stroke, traumatic brain injury, or spinal cord injury, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and inflammatory bowel disease.Type: GrantFiled: September 20, 2021Date of Patent: January 10, 2023Assignee: Landos Biopharma, Inc.Inventors: Josep Bassaganya-Riera, Andrew Leber, Nuria Tubau-Juni, Raquel Hontecillas
-
Publication number: 20220089586Abstract: Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat conditions such as autoimmune diseases, allergic diseases, chronic and/or inflammatory central nervous system diseases, chronic and/or inflammatory respiratory diseases, cancer, and infectious diseases. Exemplary conditions include multiple sclerosis, asthma, Alzheimer's disease, Parkinson's disease, neuroinflammation resulting from, for example, stroke, traumatic brain injury, or spinal cord injury, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and inflammatory bowel disease.Type: ApplicationFiled: September 20, 2021Publication date: March 24, 2022Inventors: Josep Bassaganya-Riera, Andrew Leber, Nuria Tubau-Juni, Raquel Hontecillas
-
Publication number: 20220017488Abstract: Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.Type: ApplicationFiled: September 29, 2021Publication date: January 20, 2022Applicant: Landos Biopharma, Inc.Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
-
Patent number: 11180473Abstract: Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.Type: GrantFiled: March 25, 2021Date of Patent: November 23, 2021Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
-
Publication number: 20210309635Abstract: Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.Type: ApplicationFiled: March 25, 2021Publication date: October 7, 2021Applicant: Landos Biopharma, Inc.Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni